IDiyas

For the Inventor, By the Inventor

North Potomac, MD, United States of America

Christopher J Michejda

USPTO Granted Patents = 21 


Average Co-Inventor Count = 3.2

ph-index = 6

Forward Citations = 78(Granted Patents)


Location History:

  • N. Potomac, MD (US) (1998)
  • Potomac, MD (US) (1993 - 2003)
  • North Potomac, MD (US) (1996 - 2017)

Company Filing History:

goldMedal15 out of 3,435 
 
National Institutes of Health, a Component of the US Dept. of Health & Human Services
 patents
silverMedal4 out of 1,215 
 
The United States of America As Represented by the Department of Health
 patents
bronzeMedal4 out of 1,926 
 
University System of Maryland
 patents
4. 4 out of 889 
 
The United States Government As Represented by the Department of Veterans Affairs
 patents
5. 2 out of 2,202 
 
The United States of America As Represented by the Secretary of
 patents
where one patent can have more than one assignee

Years Active: 1993-2017

Loading Chart...
Loading Chart...
21 patents (USPTO):Explore Patents
1. 9540427 - Peptide-based stat inhibitor (2017-01-10),
2. 9326950 - Self-assembling nanoparticles composed of transmembrane peptides and their application for specific intra-tumor delivery of anti-cancer drugs (2016-05-03),
3. 9085604 - Antiproliferative factor and methods of use (2015-07-21),
4. 9079936 - Derivatives of APF and methods of use (2015-07-14),
5. 8912146 - Derivatives of APF and methods of use (2014-12-16),
6. 8680056 - Antiproliferative factor and methods of use (2014-03-25),
7. 8008316 - Azonafide derived tumor and cancer targeting compounds (2011-08-30),
8. 7605125 - DNA-binding polyamide drug conjugates (2009-10-20),
9. 7517849 - Inhibition of ABC transporters by transmembrane domain analogs (2009-04-14),
10. 7105488 - G protein-coupled receptor antagonists (2006-09-12),
11. 6894068 - Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase (2005-05-17),
12. 6664263 - 1,8-naphthalimide imidazo{4,5,1-de}acridones with anti-tumor activity (2003-12-16),
13. 6541483 - Acridone-derived compounds useful as antineoplastic and antiretroviral agents (2003-04-01),
14. 6369235 - Substituted benzimidazoles, and methods of use thereof, for the inhibition of HIV reverse transcription and for the treatment of HIV infection (2002-04-09),
15. 6187775 - Acridone-derived compounds useful as antineoplastic and antiretroviral agents (2001-02-13),

Title: Christopher J. Michejda: Innovator in Peptide-Based Technologies

Introduction: Christopher J. Michejda is a prominent inventor based in North Potomac, Maryland, recognized for his significant contributions to the field of peptide-based therapies. With an impressive portfolio of 21 patents, Michejda's work focuses on innovative solutions for treating diseases associated with STAT overexpression and advancements in drug delivery systems.

Latest Patents: Among his most recent patents is a groundbreaking invention involving a peptide-based STAT inhibitor. This invention encompasses a peptide or peptidomimetic with an amino acid sequence derived from the second helix of a STAT protein. The invention details a method to inhibit STAT proteins within cells and offers potential treatments for diseases linked to STAT overexpression. Another notable patent is for self-assembling nanoparticles featuring transmembrane peptides. This invention outlines a method for effectively delivering hydrophobic anti-cancer agents via nanoparticles that self-assemble when combined with isolated peptides.

Career Highlights: Michejda has made remarkable strides in his career, collaborating with reputable organizations, including the U.S. Department of Health and Human Services and the U.S. Department of Health. His work is instrumental in advancing therapeutic strategies and enhancing the efficacy of drug delivery systems, demonstrating his expertise and dedication to innovation.

Collaborations: Throughout his career, Michejda has partnered with notable colleagues, including Nadya Tarasova and Jeffrey J. Blumenstein. These collaborations have enriched his research endeavors and fostered a creative environment for developing advanced medical solutions.

Conclusion: Christopher J. Michejda's work exemplifies the spirit of innovation in the field of peptide-based therapies and drug delivery mechanisms. His 21 patents reflect his commitment to enhancing healthcare solutions, positioning him as a key figure in the ongoing evolution of medical technology and treatment modalities.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…